Navigation Links
Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it has rescheduled its earnings call regarding its fourth quarter and year-end 2008 financial results, which was previously scheduled to be held on Thursday, March 12, 2009 at 8:30 a.m. Eastern Time, in order to complete its financial statement close and audit process. The Company will hold its conference call, issue a press release for the fourth quarter and year-ended December 31, 2008 and file its Annual Report on Form 10-K after market close on Monday, March 16, 2009.

Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, chief financial officer, and Robert De Jager, M.D., FACP, chief medical officer, will host the rescheduled call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, March 16.

To participate in the live call by telephone, please dial 877-719-9791 from the U.S. or 719-325-4811 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at A replay of the webcast will be available on the Company's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone-refractory) prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
2. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
3. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
6. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
7. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
8. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
9. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
10. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
Breaking Biology Technology:
(Date:10/4/2017)... 2017  GCE Solutions, a global clinical research organization (CRO), announces ... solution on October 4, 2017. Shadow is designed to assist medical ... policy 0070 of the European Medicines Agency (EMA) in meeting the ... ... ...
(Date:7/20/2017)... , July 20, 2017 Delta (NYSE: DAL ) ... any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board ... Delta,s biometric boarding ... Club is now integrated into the boarding process to allow eligible ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
Breaking Biology News(10 mins):